Nasopharyngeal Carcinoma Clinical Trials (July 2026): 164 Recruiting Interventional Studies

Last updated: July 1, 2026

Answer a few questions to find clinical trials matched to your specific Nasopharyngeal Carcinoma situation.

Usually 2–3 minutes. No sign-up.

Current Clinical Trial Landscape

Active research areas in 2026:

PD-1 inhibitors added to GP induction + chemoRT for locally advanced disease — multiple Phase 3 trials
EBV DNA–guided treatment stratification — de-escalation for good responders, intensification for high-risk
EGFR-targeted ADCs (MRG003 / Becotatug Vedotin) and EGFR×HER3 bispecific ADCs (BL-B01D1) — multiple Phase 3 trials in LA-NPC and recurrent/metastatic
PD-1 / CTLA-4 bispecific antibodies (cadonilimab, QL1706) added to chemoRT
Immunotherapy maintenance after induction — vs capecitabine, Phase 2
Proton therapy vs photon IMRT — non-inferiority Phase 3 trials
EBV-targeted CAR-T / TCR-T cell therapy

Standard of care: GP (gemcitabine + cisplatin) induction → concurrent chemoRT → ± adjuvant therapy. Immunotherapy (PD-1 inhibitors) increasingly standard in recurrent/metastatic setting.

Recruiting Trials by Treatment Stage

First-Line Locally Advanced (Curative Intent)

Standard treatment is GP induction + concurrent chemoRT. These trials test immunotherapy additions, radiation optimization, or EBV-guided de-escalation:

Immunotherapy + standard treatment:
- NCT06712888 - Toripalimab vs Placebo + GP induction (Phase 3)
- NCT04453826 - Camrelizumab + chemoRT vs chemoRT alone (Phase 3)
- NCT06749899 - QL1706 (PD-1/CTLA-4 bispecific) + chemoRT (Phase 3)
- NCT05941741 - Induction chemo + low-dose RT + cadonilimab (PD-1/CTLA-4 bispecific) in LA-NPC (Phase 3)
- NCT07154069 - Adaptive immunotherapy for NPC (Phase 3)
- NCT07459296 - Becotatug vedotin + sintilimab in locoregionally advanced NPC (Phase 3)
Intensified for high-risk (detectable EBV DNA):
- NCT05772208 - Camrelizumab + Nimotuzumab for EBV+ after 1 cycle GP (Phase 3)
- NCT07496190 - Becotatug vedotin for LA-NPC with suboptimal response to induction (Phase 2)
De-escalation for good responders (undetectable EBV DNA):
- NCT05674305 - RT alone vs concurrent chemoRT (Phase 3)
- NCT06092957 - Reduced-dose RT ± CCT for CR after induction (Phase 3)
- NCT04448522 - Reduced vs conventional dose IMRT (Phase 3)
- NCT06682442 - Induction chemo response-guided radiation in EBV-associated NPC
Maintenance after definitive treatment:
- NCT07392320 - Immunotherapy vs capecitabine maintenance after definitive treatment (Phase 2)
Proton therapy:
- NCT07340515 - Proton vs Photon IMRT (Phase 3)
- NCT07000643 - Proton vs Photon therapy (Phase 3, non-inferiority)

Recurrent or Metastatic

Immunotherapy + chemotherapy is becoming standard. These trials test new combinations or targets:

First-line R/M:
- NCT05854849 - Gemcitabine + Camrelizumab + Apatinib vs GP + Cisplatin (Phase 3)
Second-line+ (after immunotherapy):
- NCT06976190 - MRG003 (ADC) + Pucotenlimab vs chemo (Phase 3)
- NCT06629597 - YL201 vs docetaxel/capecitabine (Phase 3)
- NCT06259721 - Anti-PD1 + Nimotuzumab + Capecitabine (platinum-resistant)
- NCT06676722 - SBRT + Nimotuzumab + Tislelizumab (oligoprogression after IO)
Oligometastatic:
- NCT04944914 - Camrelizumab + SBRT vs Camrelizumab alone (Phase 3)
- NCT07235319 - Immediate vs salvage locoregional RT (Phase 3)

Locoregional Recurrence

For disease recurring in the nasopharynx/neck after prior treatment:

Re-irradiation:
- NCT05340491 - ChemoRT + Toripalimab vs ChemoRT alone (Phase 3)
- NCT04453813 - Toripalimab + concurrent chemoRT (Phase 3)
- NCT03907826 - PD-1 antibody + chemoRT for recurrent T3/T4 (Phase 3)
Surgery + adjuvant:
- NCT04778956 - Toripalimab + surgery vs surgery alone (Phase 3)
- NCT05877872 - Reduced-target vs full-target resection (Phase 3)
- NCT06912711 - Toripalimab + Nimotuzumab neoadjuvant/adjuvant

Novel Approaches

EBV-targeted cellular therapy:
- NCT05587543 - EBV CAR-T/TCR-T cells for NPC
ADC (antibody-drug conjugate):
- NCT06976190 - MRG003 (EGFR-ADC) + Pucotenlimab (Phase 3)
- NCT06475300 - BL-B01D1 (EGFR×HER3 bispecific ADC) + PD-1
- NCT06839066 - HLX43 (PD-L1 ADC) for R/M NPC (Phase 2)
Bispecific antibody:
- NCT06749899 - QL1706 (PD-1/CTLA-4) + chemoRT (Phase 3)

Showing selected notable trials. View all 164 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find NPC clinical trials I'm eligible for?

Paste your medical summary into ClinTrialFinder and get AI-matched NPC trials in minutes. The tool considers your EBV status, cancer stage, prior treatments, and whether you have locally advanced or metastatic disease.

What nasopharyngeal carcinoma trials are currently recruiting?

There are 164 recruiting interventional trials for nasopharyngeal carcinoma in July 2026 including 59 Phase 3 studies. Recent Phase 3: RAIRI-Model-Guided Adjuvant Therapy NCT07590024, toripalimab + capecitabine maintenance in high-risk NCT06277050, chemoRT + anti-PD1 recurrent NPC NCT05340491, IC + low-dose RT + cadonilimab LANPC NCT05941741. Active classes: immunotherapy combinations with chemoRT, EGFR-targeted ADCs (MRG003 / Becotatug Vedotin) and EGFR×HER3 bispecific ADCs (BL-B01D1), PD-1/CTLA-4 bispecific antibodies (cadonilimab, QL1706 — see bispec IO hub), EBV DNA-guided treatment de-escalation, proton therapy non-inferiority trials, and EBV-targeted CAR-T/TCR-T cell therapy.

Find NPC Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.

Find Matching Trials